Trial to enroll approximately 2,250 adults to assess safety and immunogenicity of AZD2816 against the SARS-CoV-2 virus The first participants in a Phase II/III trial for the new COVID-19 variant vaccine AZD2816 were vaccinated today to assess its safety and immunogenicity in both Read More …